2074. Analysis of Current Pharmacy Statutes and Regulations Governing Pharmacists' Authority to Administer Cabotegravir (CAB) for PrEP in the United States (US)

作者：Hailey Colangeli · 发表于：Open Forum Infectious Diseases · 年份：2022 · DOI：10.1093/ofid/ofac492.1696 · 被引用次数：3 · 研究领域：HIV/AIDS drug development and treatment、Pneumocystis jirovecii pneumonia detection and treatment、HIV/AIDS Research and Interventions

Abstract Background The Ending the HIV Epidemic initiative aims to increase PrEP use among eligible Americans to 50% by 2030. As one of the most widely accessible healthcare providers, pharmacists are well positioned to support these efforts. The latest advancement in HIV prevention—long-acting injectable CAB for PrEP—offers a novel solution to the adherence challenges of oral regimens. Understanding the current landscape of medication administration privileges for pharmacists is critical to facilitating uptake of CABr and preventing HIV transmission. Methods This was a cross sectional analysis of state pharmacy statues and regulations from 50 US states and the District of Columbia (States). Data were obtained from publicly accessible, official websites of the regulatory agencies with jurisdiction over the practice of pharmacy in each respective state. We analyzed current laws in effect as of February, 2022 in accordance with best practices for legal mapping. Using a standardized analysis algorithm, we determined the impact of state laws on pharmacists’ ability to administer CAB. Results Current state legislature allows administration of CAB by pharmacists in 44 States (80.3%). Broad authority is granted in 28 states (55.0%) where administration is defined within scope of practice. In 5 states, pharmacists can administer injectable medications if the prescription order contains explicit instructions for pharmacist administration, or a standing protocol. Among 8 states that re...